newsfilter
← Latest News
Business Wire·

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 2seventy bio, Inc. (NASDAQ:TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a